Circulation. Genomic and precision medicine
Mavacamten Monotherapy in Real-World Patients With Obstructive Hypertrophic Cardiomyopathy: Evidence From COLLIGO-HCM.
Ozlem Bilen, Arnon Adler, Rachel Bastiaenen, James P MacNamara, Elizabeth Paratz, Elad Maor, Michael Arad, Matthew Gold, Nirav Patel, Cliff Pruett, Edward Burford, Garima Arora, Ervant J Maksabedian Hernandez, Xu Han, Patricia Schuler
Published: 202510.1161/CIRCGEN.125.005502
Abstract
BACKGROUND: Mavacamten has been shown to improve cardiac function and symptoms in patients with symptomatic (New York Heart Association class II-III) obstructive hypertrophic cardiomyopathy (HCM). Clinical studies suggest that mavacamten monotherapy…
Preview only. Read the full abstract at the source